Clinical trial
A Phase 1b/2a Study To Evaluate The Safety Of CMTX-101 In Combination With Inhaled Antibiotics In People With Cystic Fibrosis Chronically Infected With Pseudomonas Aeruginosa
NCT06159725 is registered in ClinicalTrials.gov with Clarametyx Biosciences, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b/2a Study To Evaluate The Safety Of CMTX-101 In Combination With Inhaled Antibiotics In People With Cystic Fibrosis Chronically Infected With Pseudomonas Aeruginosa
- Lead sponsor
- Clarametyx Biosciences, Inc.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- June 24, 2024
- Completion date
- November 14, 2025
- Enrollment
- 43 (actual)
- Sites
- 23
Conditions
As the registry lists them; a condition with its own page is linked.